Merck & Co, Inc announced today that it have submit to the U.S. Food and Drug Administration (FDA) a Biologics License Application contained by favour of ZOSTAVAX(reg) [zoster vaccine singing (Oka/Merck)], an investigational vaccine for the restraint of herpes zoster, traditionally practised in place of “shingles;” prevention of postherpetic neuralgia (PHN), the ruthless, [...]
Entries from July 2008
Shingles and Shingles-Associated Nerve Pain, ZOSTAVAX(reg) Submitted to FDA for Biologics Licence
July 3rd, 2008 · No Comments
Tags: herpes simplex 1
